Drugmakers, PhRMA, BIO Push Back Against FDA Proposal for Nonclinical GLPs

Several large drugmakers and industry groups commented on FDA’s proposal to require higher quality management standards for nonclinical studies used to support product applications.
Source: Drug Industry Daily